← Back to Search

Imaging

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer (PET ABC Trial)

N/A
Waitlist Available
Led By Ian Dayes, MD
Research Sponsored by Ontario Clinical Oncology Group (OCOG)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization to date of event, assessed up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is comparing two methods to see how far Stage III breast cancer has spread. One method uses a special scan, and the other uses the usual tests doctors perform. The goal is to find out which method is better for planning treatment.

Eligible Conditions
  • Breast cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 5 years from date of randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 5 years from date of randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients upstaged to Stage IV disease
Secondary study objectives
Disease Free Survival
Incremental economic analysis comparing the costs and outcomes of the treatment arms
Overall Survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Whole-body FDG PET-CT aloneExperimental Treatment1 Intervention
Group II: Conventional breast cancer stagingActive Control1 Intervention
Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen \& pelvis

Find a Location

Who is running the clinical trial?

Ontario Clinical Oncology Group (OCOG)Lead Sponsor
64 Previous Clinical Trials
41,718 Total Patients Enrolled
Cancer Care OntarioOTHER
16 Previous Clinical Trials
91,664 Total Patients Enrolled
Ian Dayes, MDPrincipal InvestigatorJuravinski Hospital and Cancer Centre
1 Previous Clinical Trials
103 Total Patients Enrolled
Andrea Eisen, MDPrincipal InvestigatorSunnybrook Health Sciences Centre
1 Previous Clinical Trials
100 Total Patients Enrolled
Ralph George, MDPrincipal InvestigatorSt. Michael's Hospital, CIBC Breast Centre
Mark Levine, MDStudy DirectorOntario Clinical Oncology Group (OCOG)
16 Previous Clinical Trials
8,861 Total Patients Enrolled
Ur Metser, MDPrincipal InvestigatorPrincess Margaret Hospital, Canada
6 Previous Clinical Trials
410 Total Patients Enrolled
~41 spots leftby Dec 2025